Results 71 to 80 of about 10,125,713 (289)

Evaluation of liver stiffness measurement–based scores in liver transplantation recipients

Liver Transplantation, EarlyView., 2022
Abstract Combining bioclinical parameters with liver stiffness measurement (LSM) has improved the diagnostic performance of vibration‐controlled transient elastography (VCTE) for detection of advanced fibrosis in patients with chronic liver disease. However, this approach has not yet been tested in liver transplantation (LT) recipients.
Tamoore Arshad, Chandra S. Bhati, Anh T. Bui, Michael Tseng, Dylan Vainer, Austin Miller, Marie‐Claire Evans, Taseen Syed, Vaishali Patel, Michael O. Idowu, Mark Muthiah, Mohammad Shadab Siddiqui   +11 more
wiley   +1 more source

Therapeutic approaches for non-alcoholic steatohepatitis

Therapeutic Advances in Endocrinology and Metabolism, 2021
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have been reported as a novel worldwide epidemic, very often associated with obesity, metabolic syndrome, and type 2 diabetes.
Luc F. Van Gaal, Jonathan Mertens, Sven Francque, Christophe De Block   +3 more
doaj   +1 more source

ROS/pH‐Responsive Phenylboronic Acid–Chitosan Nanoparticles Improve Silymarin‐Mediated Hepatoprotection After Hepatectomy With Gut‐Liver Axis‐Associated Responses

Advanced Science, EarlyView.
Bioactive phenylboronic acid–chitosan nanoparticles enable responsive silymarin delivery for post‐hepatectomy liver protection. The nanoplatform integrates antioxidant and antibacterial functions, improves hepatic recovery, and is associated with coordinated shifts in gut microbiota, metabolites, cytokines, and hepatic proteomic pathways, suggesting a ...
Jinjin Tong, Chaochao Luo, Zezheng Liu, Xinyan Zhang, Daixu Jia, Yang Sun, Zhaonan Zhang, Haoran Shi, Jianfang Wang, Hua Zhang   +9 more
wiley   +1 more source

Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis [PDF]

, 2021
Non-alcoholic steatohepatitis has emerged as a major public health problem, and the burden of non-alcoholic steatohepatitis cirrhosis is projected to increase by 64%-156% by 2030.
Salvador Augustin, Bugianesi, Elisabetta, Elisabetta Bugianesi, Angelo Armandi, Armandi, A., Jesús Rivera‐Esteban, Augustin Recio, Salvador, Rivera-Esteban, Jesús, Armandi, Angelo, Bugianesi, E.   +9 more
core   +1 more source

A Hepatocyte‐to‐Stellate Cell Axis Couples Alternate‐Day Fasting to Liver Fibrosis Resolution via ATG7 S‐Nitrosylation

Advanced Science, EarlyView.
Alternate‐day fasting suppresses mitochondrial complex II assembly via SDHAF4 to upregulate hepatocyte eNOS. The resulting nitric oxide S‐nitrosylates ATG7 at C184 in hepatic stellate cells, restraining autophagic flux and preventing their profibrotic activation.
Xueqiang Wang, Mengqi Zeng, Cunxiao Sun, Yuhan Gou, Zhaode Feng, Weiqiang Lv, Chaoying Yan, Hansen Wu, Pengfei Zhang, Jie Xu, Ke Cao, Hao Li, Mingge Ding, Zhongbo Liu, Xing Zhang, Jiankang Liu, Xuan Zou, Zhihui Feng   +17 more
wiley   +1 more source

Viability assessment and transplantation of fatty liver grafts using end‐ischemic normothermic machine perfusion

Liver Transplantation, EarlyView., 2022
Abstract End‐ischemic viability testing by normothermic machine perfusion (NMP) represents an effective strategy to recover liver grafts having initially been discarded for liver transplantation (LT). However, its results in the setting of significant (≥30%) macrovesicular steatosis (MaS) have not been specifically assessed.
Damiano Patrono, Riccardo De Carlis, Alessandro Gambella, Francesca Farnesi, Alice Podestà, Andrea Lauterio, Francesco Tandoi, Luciano De Carlis, Renato Romagnoli   +8 more
wiley   +1 more source

Avaliação histopatológica hepática em pacientes obesos mórbidos submetidos à cirurgia bariátrica [PDF]

, 2004
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Pastro, Dalto Antonio Viganó
core  

FBP1‐Mediated Compartmentalization of Glycolytic Enzyme Complexes Suppresses PKM2 Function to Ameliorate MASLD Progression

Advanced Science, EarlyView.
In normal hepatocytes, FBP1 forms compartmentalized complexes with PKM2, ENO1, and LDHA independent of its catalytic activity, inhibiting PKM2 activity and restricting excessive glycolysis. During MASLD progression, FBP1 downregulation markedly reduces the abundance of these complexes and releases the “hijacked” glycolytic enzymes, leading to PKM2 ...
Busong Wang, Yiping Tang, Na Li, Xuening Dai, Jing Wu, Bin Xue, Yuxin Chen, Jingzi Zhang, Lingdong Kong, Chaojun Li, Lei Fang   +10 more
wiley   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Epidemiology of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A focused literature review

JGH Open, 2020
Non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) represent a growing unmet medical need and an increasingly prevalent cause of cirrhosis, hepatocellular carcinoma (HCC), and death in Japan.
Yuichiro Eguchi, Gabriel Wong, Emma (I‐Heng) Lee, Omar Akhtar, Ricardo Lopes, Yoshio Sumida   +5 more
doaj   +1 more source